Newsroom

The latest news, information and stories from Johnson & Johnson Innovative Medicine UK.

The Newsroom is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public.

Press Releases

Sorry, I don't understand. Please try again

Immunology

19 September 2025

Icotrokinra shows superiority to deucravacitinib in the first reported head-to-head trials of investigational targeted oral peptide for the treatment of plaque psoriasis

For UK medical and pharmaceutical trade media only

Read more
28 August 2025

NICE issues final guidance recommending TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis in the UK

For UK medical and pharmaceutical trade media only

Read more
Oncology

12 May 2025

SMC approval of BALVERSA®▼ (erdafitinib) helps pave the way for first licensed bladder cancer therapy that specifically targets fibroblast growth factor receptor (FGFR3) alterations

For medical and pharmaceutical trade media

Read more
Oncology

02 May 2025

NICE recommends BALVERSA®▼ (erdafitinib) in Final Draft Guidance, the first and only treatment in the UK for metastatic or unresectable fibroblast growth factor receptor (FGFR3)-altered urothelial cancer (UC) for patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor

For UK national, medical and pharmaceutical trade media

Read more
Oncology

27 March 2025

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations versus osimertinib

For UK medical and pharmaceutical trade media only

Read more
Oncology

19 March 2025

MHRA grants marketing authorisation for LAZCLUZE®▼ (lazertinib) in combination with RYBREVANT®▼ (amivantamab) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations

For UK medical and pharmaceutical trade media only

Read more
Immunology

21 February 2025

TREMFYA® (guselkumab) subcutaneous (SC) induction data support the potential to become the first in its class to offer the option of both intravenous (IV) and SC induction therapy in ulcerative colitis

For UK medical and trade media only For immediate release

Read more
Oncology

06 November 2024

MHRA grants marketing authorisation for BALVERSA®▼ (erdafitinib) as monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC) harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting

For UK medical and pharmaceutical trade media only

Read more
Immunology

29 October 2024

TREMFYA® (Guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease

For UK medical and trade media only For immediate release

Read more
Immunology

17 October 2024

Johnson & Johnson transitions Remicade® (infliximab) and Simponi® (golimumab) for treatment of patients with Inflammatory Diseases

MEDIA STATEMENT FOR UK MEDICAL AND TRADE MEDIA ONLY For Immediate Release

Read more

CP-491724 | September 2025